2 active not recruiting, 1 completed, 1 withdrawn. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow Sarcomas: new trials by email Literature Review of Sarcomas trials Research Report on Sarcomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa, Azacytidine - Sarcomas, Melanomas | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2021-12-14 | 2021-12-17 | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC ONC-392, Pembrolizumab, Docetaxel - Non Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | OncoC4, Inc. | 733 | 2020-09-16 | 2026-09-14 |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Entrectinib - Breast Cancer, Cholangiocarcinoma | Phase 2 | Active not recruiting | Hoffmann-La Roche | 534 | 2015-11-19 | 2026-08-25 |
| Dendritic Cell Vaccination for Patients with Solid Tumors autologous dendritic cell vaccination - Glioblastoma, Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | University Hospital, Antwerp | 48 | 2010-05-03 | 2024-12-09 |
Carcinoma, Renal Cell (4) · Sarcoma (4) · Breast Neoplasms (3) · Colorectal Neoplasms (3) · Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Salivary Gland Neoplasms (2) · Brain Neoplasms (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Glioblastoma (1)
Adenocarcinoma (4) · Carcinoma (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Kidney Diseases (4) · Kidney Neoplasms (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Connective and Soft Tissue (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Skin Diseases (4)
Azacitidine (1) · Docetaxel (1) · bintrafusp alfa protein, human (1) · entrectinib (1) · pembrolizumab (1)
Hoffmann-La Roche (1) · National Cancer Institute (NCI) (1) · OncoC4, Inc. (1) · University Hospital, Antwerp (1)
United States (3) · Australia (2) · Belgium (2) · China (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1)
David S Schrump, M.D. (1) · Tianhong Li, MD (1)
PMID 29118225, PMID 31838007, PMID 31838015, PMID 33646820, PMID 34427452, PMID 34924145, PMID 36924196, PMID 38848521, PMID 39549678, PMID 40086048, PMID 40341199
2015 (1), R44CA250824 (1)